

November 7, 2013

Dynavax Reports Third Quarter 2013 Financial Results

BERKELEY, CA -- (Marketwired) -- 11/07/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2013. The Company had \$76.5 million in cash, cash equivalents and marketable securities as of September 30, 2013, compared to \$125.1 million at December 31, 2012.

For both quarters ended September 30, 2013 and 2012, Dynavax reported total revenues of \$2.9 million. Total revenues for the nine months ended September 30, 2013 were \$8.4 million compared to \$7.9 million for the same period in 2012.

General and administrative expenses for the quarter ended September 30, 2013 were \$5.8 million compared to \$7.1 million for the third quarter of 2012. For the nine months ended September 30, 2013, general and administrative expenses were \$22.2 million compared to \$18.9 million for the same period in 2012. This increase was due to one-time cash and non-cash stock-based severance costs of \$2.0 million and \$7.5 million, respectively, for the third quarter and nine month period of 2013. General and administrative expenses other than these organizational transition costs decreased by 49% during the third quarter and 24% for the nine month period of 2013.

Research and development expenses for the quarter ended September 30, 2013 were \$11.8 million compared to \$12.9 million for the third quarter of 2012. For the nine months ended September 30, 2013, research and development expenses were \$38.7 million compared to \$36.6 million for the same period in 2012. This increase was due primarily to manufacturing activities and expenses related to the supply of HEPLISAV™.

On October 30, 2013, the Company sold 79,570,000 shares of our common stock at a price of \$1.075 per share and 43,430 shares of the Company's Series B Convertible Preferred Stock (Series B) for a price of \$1,075.00 per share, in separate, concurrent underwritten public offerings. The sale of the common stock and Series B resulted in aggregate net proceeds to us of approximately \$125 million after deducting estimated commissions and offering expenses.

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases and cancer. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.

DYNAVAX TECHNOLOGIES CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)

	<i>Three Months Ended September 30,</i>		<i>Nine Months Ended September 30,</i>	
	<i>2013</i>	<i>2012</i>	<i>2013</i>	<i>2012</i>
Revenues:				
Collaboration revenue	\$ 1,110	\$ 1,050	\$ 3,349	\$ 3,602
Grant revenue	1,700	1,219	3,855	3,188
Service and license revenue	117	605	1,200	1,118
Total revenues	<u>2,927</u>	<u>2,874</u>	<u>8,404</u>	<u>7,908</u>
Operating expenses:				
Research and development	11,770	12,850	38,739	36,631
General and administrative	5,807	7,121	22,243	18,871
Unoccupied facility expense	918	--	918	--
Total operating expenses	<u>18,495</u>	<u>19,971</u>	<u>61,900</u>	<u>55,502</u>
Loss from operations	(15,568)	(17,097)	(53,496)	(47,594)
Interest income	37	91	163	208

Interest expense	(24)	(589)	(83)	(1,765)
Other income (expense)	(120)	(196)	(248)	(255)
Net loss	<u>\$ (15,675)</u>	<u>\$ (17,791)</u>	<u>\$ (53,664)</u>	<u>\$ (49,406)</u>
Basic and diluted net loss per share	<u>\$ (0.09)</u>	<u>\$ (0.10)</u>	<u>\$ (0.29)</u>	<u>\$ (0.30)</u>
Shares used to compute basic and diluted net loss per share	<u>183,022</u>	<u>177,870</u>	<u>182,960</u>	<u>167,039</u>

DYNAVAX TECHNOLOGIES CORPORATION
SELECTED CONSOLIDATED BALANCE SHEET DATA
(In thousands)
(Unaudited)

	<u>September 30,</u> <u>2013</u>	<u>December 31,</u> <u>2012</u>
Assets		
Cash, cash equivalents and marketable securities	\$ 76,474	\$ 125,130
Property and equipment, net	8,454	7,965
Goodwill	2,532	2,475
Other assets	<u>4,238</u>	<u>4,182</u>
Total assets	<u>\$ 91,698</u>	<u>\$ 139,752</u>
Liabilities and stockholders' equity		
Deferred revenues	\$ 8,877	\$ 12,068
Other liabilities	<u>10,425</u>	<u>12,858</u>
Total liabilities	19,302	24,926
Stockholders' equity	<u>72,396</u>	<u>114,826</u>
Total liabilities and stockholders' equity	<u>\$ 91,698</u>	<u>\$ 139,752</u>

Contacts:

Michael Ostrach
Vice President and Chief Business Officer
510-665-7257
[Email Contact](#)

Source: Dynavax Technologies

News Provided by Acquire Media